William Blair Investment Management LLC trimmed its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report) by 40.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 139,075 shares of the medical equipment provider’s stock after selling 93,522 shares during the quarter. William Blair Investment Management LLC’s holdings in Lantheus were worth $13,842,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors have also bought and sold shares of the business. ABS Investment Management LLC bought a new position in shares of Lantheus during the second quarter valued at approximately $232,974,000. Western Wealth Management LLC purchased a new stake in shares of Lantheus in the 1st quarter worth approximately $25,000. USA Financial Formulas bought a new position in Lantheus during the 3rd quarter valued at approximately $41,000. Allworth Financial LP bought a new position in Lantheus during the 2nd quarter valued at approximately $49,000. Finally, Bessemer Group Inc. increased its position in Lantheus by 221.2% during the 1st quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 354 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.
Lantheus Price Performance
Shares of LNTH opened at $101.59 on Monday. The firm has a market cap of $6.64 billion, a PE ratio of 25.02 and a beta of 0.01. The company has a current ratio of 3.25, a quick ratio of 3.06 and a debt-to-equity ratio of 0.42. The firm has a fifty day simple moving average of $100.32 and a two-hundred day simple moving average of $92.91. Lantheus Holdings, Inc. has a 1-year low of $51.47 and a 1-year high of $111.86.
Lantheus (NASDAQ:LNTH – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The medical equipment provider reported $1.68 EPS for the quarter, topping the consensus estimate of $1.23 by $0.45. The company had revenue of $389.91 million during the quarter, compared to analyst estimates of $355.74 million. Lantheus had a return on equity of 29.26% and a net margin of 17.28%. Lantheus’s revenue was up 1.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.27 earnings per share. On average, equities analysts anticipate that Lantheus Holdings, Inc. will post 4.54 EPS for the current year.
Analyst Ratings Changes
Several brokerages have recently weighed in on LNTH. Mizuho downgraded Lantheus from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $115.00 to $109.00 in a report on Tuesday, October 13th. Weiss Ratings cut shares of Lantheus from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, October 15th. Brookline Capital Markets downgraded shares of Lantheus from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Leerink Partners set a $102.50 price objective on shares of Lantheus in a research note on Monday, August 3rd. Finally, B. Riley Financial cut shares of Lantheus from a “buy” rating to a “hold” rating in a report on Monday, August 17th. Three investment analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company. Based on data from MarketBeat, Lantheus currently has a consensus rating of “Hold” and a consensus target price of $107.44.
View Our Latest Stock Analysis on Lantheus
About Lantheus
Lantheus Holdings is a radiopharmaceutical and medical imaging company that develops, manufactures, and commercializes products used to diagnose and manage disease. Its offerings support imaging across several areas of medicine, including oncology and cardiology. The company’s products include Pylarify, a positron emission tomography (PET) imaging agent used to detect prostate cancer; Definity, an ultrasound contrast agent used in cardiac imaging; and TechneLite, a generator that supplies technetium-99m for diagnostic imaging procedures.
Read More
- Five stocks we like better than Lantheus
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report).
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.
